# EDGAR Filing Document

**Accession Number:** 0001589150
**File Stem:** 0001607062-23-000078
**Filing Date:** 2023-2
**Character Count:** 4596
**Document Hash:** 63b74be71a522c26a00e5d225ca5048e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001607062-23-000078.hdr.sgml**: 20230207

**ACCESSION NUMBER**: 0001607062-23-000078

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230206

**ITEM INFORMATION**: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

**FILED AS OF DATE**: 20230207

**DATE AS OF CHANGE**: 20230207

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Regen BioPharma Inc
- **CENTRAL INDEX KEY:** 0001589150
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 455192997
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 333-191725
- **FILM NUMBER:** 23592764

**BUSINESS ADDRESS:**
- **STREET 1:** 4700 SPRING ST #304
- **CITY:** LA MESA
- **STATE:** CA
- **ZIP:** 91942
- **BUSINESS PHONE:** 619-722-5505

**MAIL ADDRESS:**
- **STREET 1:** 4700 SPRING ST #304
- **CITY:** LA MESA
- **STATE:** CA
- **ZIP:** 91942

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 6, 2023

**<u>REGEN BIOPHARMA, INC.</u>**

(Exact name of small business issuer as specified in its charter)

---

| | |
|:---|:---|
| **<u>Nevada</u>** | **<u>45-5192997</u>** |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |

---

Commission File No. **333-191725**

**<u>4700 Spring Street, St 304, La Mesa, California 91942</u>**

(Address of Principal Executive Offices)

**<u>(619) 722 5505</u>**

(Issuer's telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
|  | **None** |  |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.03 Amendments to Articles of Incorporation**

On February 6, 2023 Regen Biopharma, Inc. (the "Company") filed with the Nevada Secretary of State

&nbsp;&nbsp;&nbsp;&nbsp;**(a)** An
 amendment to the Certificate of Designations of the Company's Series AA Preferred Stock
 reducing that number of votes per share of Series AA Preferred stock to seven votes per share
 as of March 6, 2023.

&nbsp;&nbsp;&nbsp;&nbsp;**(b)** An
 amendment to the Certificate of Designations of the Company's Series NC Preferred Stock
 reducing that number of votes per share of Series NC Preferred stock to three hundred and
 thirty four votes per share as of March 6, 2023

&nbsp;&nbsp;&nbsp;&nbsp;**(c)** A
 Certificate of Change authorizing 1 for 1500 reverse stock split of all issued series of
 stock. One share of Common Stock will be issued after the exchange for one thousand five
 hundred shares of Common Stock issued. One share of each series of Preferred Stock will be
 issued after the exchange for one thousand five hundred shares of each series of Preferred
 Stock issued. The reverse stock split shall become effective March 6, 2023.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
|  | **REGEN BIOPHARMA, INC.** |
| Dated: February 7, 2023 | *<u>By: /s/ David Koos</u>* |

---